TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23623047
Drug: Olmesartan at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan at 20 mg/day
Study: 23623047
Drug: Valsartan at
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan at 80 mg/day
Study: 20955210
Drug: Low-dose fenoldopam
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fenoldopam infusion
Study: 19164400
Drug: Pulmonary rehabilitation
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary rehabilitation (exercise training twice weekly for 12 weeks, nutritional and self-care advice, education about disease and energy conservation)
Study: 8377777
Drug: Broad-spectrum sunscreen
Normalized name: Titanium Dioxide 0.08 g in 1 g TOPICAL LOTION [ZO MEDICAL OCLIPSE-C Broad-Spectrum Sunscreen SPF 50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum sunscreen cream with SPF 17
Study: 21928714
Drug: Base cream
Normalized name: U-Base Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Base cream (control)
Study: 3535685
Drug: Bronchodilator (salbutamol)
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bronchodilator (salbutamol)
Study: 20420955
Drug: Cognitive-behavioural intervention;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural intervention; details on dosage and duration not specified.
Study: 2685660
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of gangliosides (Cronassial)
Study: 25337948
Drug: Guided Internet-delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided Internet-delivered cognitive behavior therapy (ICBT) for insomnia
Study: 25337948
Drug: Guided Internet-delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided Internet-delivered cognitive behavior therapy (ICBT) for depression
Study: 20079223
Drug: Domestic Orlistat
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Domestic Orlistat 120 mg 3 times a day with an energy-controlled diet for 24 weeks
Study: 20079223
Drug: Imported Orlistat
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imported Orlistat 120 mg 3 times a day with an energy-controlled diet for 24 weeks
Study: 1309865
Drug: DMSA (1050
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMSA (1050 mg/m2 per day for 5 days)
Study: 1309865
Drug: CaNa2EDTA (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: CaNa2EDTA (1000 mg/m2 per day intravenously)
Study: 1309865
Drug: DMSA (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMSA (350 or 700 mg/m2 per day for 14 days on outpatient basis)
Study: 1329491
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg naloxone
Study: 6331037
Drug: 4.8 mg
Normalized name: menthol 4.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.8 mg naloxone
Study: 18344081
Drug: Lornoxicam/morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam/morphine
Study: 10700888
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with interferon or interleukin-2
Study: 10700888
Drug: Adjuvant interferon-alpha
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant interferon-alpha administration
Study: 10700888
Drug: Cisplatin-based treatment
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based treatment protocols
Study: 10700888
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose chemotherapy with autologous stem-cell support
Study: 10700888
Drug: Neoadjuvant androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant androgen depletion treatment
Study: 6362585
Drug: Fibronectin-rich plasma
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibronectin-rich plasma cryoprecipitate (2.139 +/‐ 0.161 mg/ml)
Study: 6362585
Drug: Fibronectin-poor cryoprecipitate
Normalized name: Fibronectin
DrugBank: Fibronectin (DB15150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibronectin-poor cryoprecipitate extracted plasma (placebo, 0.116 +/‐ 0.025 mg/ml)
Study: 3887350
Drug: Nd‐YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd‐YAG laser treatment
Study: 16003229
Drug: Chronic corticosteroid
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic corticosteroid therapy (CCST)
Study: 18077495
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nifedipine capsule
Study: 12925475
Drug: Ibuprofen 15
Normalized name: Ibuprofen 150 mg and paracetamol 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 15 mg/kg
Study: 26316567
Drug: Rescue therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue therapy with intra-arterial rtPA
Study: 19857068
Drug: Fenugreek bread
Normalized name: FENUGREEK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenugreek bread (5% fenugreek, 56 g)
Study: 17577460
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with doxazosin and finasteride
Study: 11562727
Drug: Scheme I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheme I: chloroquine phosphate (150 mg) at 25mg/kg/day for three days (10mg/kg on day 1, 7.5mg/kg on days 2 and 3) plus primaquine (15 mg) at 0.25mg/kg/day for fourteen days
Study: 11562727
Drug: Scheme II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheme II: chloroquine in a single dose of 10mg/kg plus primaquine at 0.5mg/kg/day for seven days
Study: 11562727
Drug: Scheme III:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheme III: chloroquine in a single dose of 10mg/kg plus primaquine at 0.5mg/kg/day for five days
Study: 8162980
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy at 2 l.min‐1 at rest
Study: 8162980
Drug: Daily activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily activities (as reported in questionnaire)
Study: 8162980
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy (prescribed based on blood gas measurements at rest)
Study: 4939600
Drug: Salbutamol 4
Normalized name: Salbutamol 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 4 mg four times daily for four weeks
Study: 4939600
Drug: Salbutamol 2
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol 2 mg four times daily for four weeks
Study: 27317878
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of tenofovir disoproxil fumarate/lamivudine/efavirenz 300/300/600 mg
Study: 23783829
Drug: Self‐administered implementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐administered implementation intention
Study: 16825290
Drug: Intramyocardial injections
Normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramyocardial injections of VEGF‐A(165) plasmid followed by G‐CSF (10 microg/kg/day for 6 days)
Study: 16825290
Drug: Intramyocardial injections
Normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramyocardial injections of VEGF‐A(165) plasmid
Study: 16825290
Drug: Intramyocardial injections
Normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramyocardial injections of placebo
Study: 15210258
Drug: Drug consultations
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug consultations in French and Bambara
Study: 8269656
Drug: Blood flow
Normalized name: NITRIC OXIDE 400 mg in 500 mg TOPICAL CAPSULE [Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood flow rate of 250 cc/min
Study: 8269656
Drug: Blood flow
Normalized name: NITRIC OXIDE 400 mg in 500 mg TOPICAL CAPSULE [Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood flow rate of 350 cc/min
Study: 8269656
Drug: Blood flow
Normalized name: NITRIC OXIDE 400 mg in 500 mg TOPICAL CAPSULE [Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood flow rate of 450 cc/min
Study: 8269656
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between the three different blood flow rates (250, 350, 450 cc/min)
Study: 30445682
Drug: Synergy 1
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synergy 1 (10 g)
Study: 19019658
Drug: O(2)/N(2)O FGF
Approvals — FDA: no, EMA: no, PMDA: no
Description: O(2)/N(2)O FGF setting change from 6 to 0.7 L per minute after three minutes
Study: 12805060
Drug: therapy‐related AML
Approvals — FDA: no, EMA: no, PMDA: no
Description: therapy‐related AML (t‐AML)
Study: 10739409
Drug: 1.0 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/day of haloperidol
Study: 10739409
Drug: 2.5 mg/day
Normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/day of haloperidol
Study: 10739409
Drug: 5.0 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg/day of haloperidol (for non-responders)
Study: 8796820
Drug: Intravenous fluid
Normalized name: Intravenous fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluid bolus with 1 L of normal saline administered over 30 minutes
Study: 3127916
Drug: Intravenous DDAVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous DDAVP (0.3 micrograms/Kg)
Study: 3127916
Drug: Subcutaneous DDAVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous DDAVP (0.3 micrograms/Kg)
Study: 16547088
Drug: Ropivacaine 2
Normalized name: fentanyl-ropivacaine 2 mcg/mL-0.1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 2 mg ml(-1) (0.2%)
Study: 16547088
Drug: Prilocaine 5
Normalized name: prilocaine 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prilocaine 5 mg ml(-1) (0.5%)
Study: 10924807
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose fentanyl (112 microg bolus followed by 0.04 microg/kg per min infusion)
Study: 10924807
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose fentanyl (56 microg bolus followed by 0.02 microg/kg per min infusion)
Study: 10924807
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (50 cc bolus followed by 45 cc/h infusion)
Study: 7717552
Drug: Fentanyl (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (both doses)
Study: 7796344
Drug: 100 IU
Normalized name: Vitamin E 100 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 IU of salmon calcitonin intranasally daily for 1 year
Study: 7796344
Drug: Placebo intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intranasal spray daily for 1 year
Study: 2121325
Drug: Nitroglycerin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (1.5 micrograms/kg/min) with oral captopril (63 +/- 8 mg/day)
Study: 619947
Drug: Clonidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (300 μg)
Study: 619947
Drug: UK-14,304 (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK-14,304 (750 μg)
Study: 19628319
Drug: High-dose B
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose B vitamin capsule (40 mg of folic acid, 100 mg of vitamin B6, and 2 mg of vitamin B12)
Study: 16733228
Drug: Doxazosin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (1 mg/day)
Study: 14998605
Drug: Declined entry
Normalized name: Sentry HC Worm X DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Declined entry into randomised clinical trials of adjuvant cancer therapy
Study: 11150899
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg diazepam
Study: 28712786
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) for 12 months
Study: 3630891
Drug: No aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspirin pretreatment
Study: 17542110
Drug: Micronutrient supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient supplement containing vitamin A, vitamin B2, vitamin B6, vitamin B12, folic acid, niacin, calcium pantothenate, vitamin C, vitamin E, iron, lysine, and calcium, daily for 9 months
Study: 12594004
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 50 mg denaverine hydrochloride
Study: 12594004
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 50 mg denaverine hydrochloride in aqueous solution
Study: 12594004
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of 50 mg denaverine hydrochloride in aqueous solution
Study: 12594004
Drug: Suppository formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppository formulation of 50 mg denaverine hydrochloride
Study: 9360031
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (30 min, 3-4 times weekly for 6 weeks)
Study: 1551298
Drug: Phenylpropanolamine hydrochloride
Normalized name: Phenylpropanolamine Hydrochloride
DrugBank: Phenylpropanolamine (DB00397)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylpropanolamine hydrochloride 25 mg p.o. four times a day (total, 10 doses)
Study: 3838406
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg of SIN-1
Study: 30861550
Drug: Prophylactic dose
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic dose apixaban
Study: 30202851
Drug: DZX +
Normalized name: Diazepam
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DZX + metformin (DZX + MTF)
Study: 30202851
Drug: DZX treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DZX treatment
Study: 24811940
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume ≤6 ml/kg PBW
Study: 24811940
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume ≥10 ml/kg PBW
Study: 20670085
Drug: FDR gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDR gemcitabine (1,000 mg/m² on days 1 and 15), oxaliplatin (60 mg/m² on days 1 and 15), capecitabine (1,000 mg/m² BID on days 1-7 and 15-21)
Study: 19440076
Drug: Nicotine administered
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine administered by cigarette smoking
Study: 19440076
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of nicotine gum
Study: 17342790
Drug: Lavender inhalation
Normalized name: LAVENDER
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lavender inhalation
Study: 17342790
Drug: Sunflower inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower inhalation
Study: 15041620
Drug: Tramadol 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 40 mg (Group T(40))
Study: 15041620
Drug: Tramadol 100
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 100 mg (Group T(100))
Study: 15041620
Drug: Tramadol 200
Normalized name: TRAMADOL 200MG (RYZOLT) SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 200 mg (Group T(200))
Study: 11352774
Drug: Lexipafant (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lexipafant (10 mg) administered intravenously over 5 min
Study: 11352774
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously over 5 min
Study: 8491237
Drug: Ambroxol 250
Normalized name: AMBROXOL
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol 250 mg b.d.
Study: 8491237
Drug: Ambroxol 500
Normalized name: AMBROXOL
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol 500 mg b.d.
Study: 31812327
Drug: Four-session intervention
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-session intervention alongside treatment-as-usual (TAU)
Study: 31812327
Drug: Treatment-as-usual (TAU)-only
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (TAU)-only
Study: 26013300
Drug: Hemoglobin transfusion
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin transfusion threshold of 70 g/L
Study: 26013300
Drug: Hemoglobin transfusion
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin transfusion threshold of 90 g/L
Study: 23374004
Drug: 153Sm isotope
Normalized name: 153SM
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 153Sm isotope monotherapy
Study: 23374004
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (153Sm + EBRT)
Study: 19873913
Drug: Eye acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye acupuncture combined with oral administration of compound Danshen tablets
Study: 19873913
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of compound Danshen tablets
Study: 16835737
Drug: Steroids/local anaesthetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids/local anaesthetics
Study: 15213584
Drug: Methylphenidate plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate plus psychosocial treatment (parent training, counseling, social skills training, academic assistance, psychotherapy)
Study: 15213584
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (including methylphenidate alone and with psychosocial treatment)
Study: 30211929
Drug: Transendocardial injection
Normalized name: ALCOHOL 80 mL in 100 mL TRANSENDOCARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transendocardial injection of autologous bone marrow-derived CD133+ stem cells
Study: 25594550
Drug: Parathyroid hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parathyroid hormone (PTH) levels above the upper limit of normal (65 pg/mL)
Study: 20838324
Drug: FAM regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAM regimen (5‐fluorouracil 600 mg/m(2) IV drip on days 1, 8, 29, and 36; doxorubicin 30 mg/m(2) IV bolus injection on days 1 and 29; mitomycin‐C 10 mg/m(2) IV bolus injection on day 1; repeated every 8 weeks)
Study: 20838324
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX regimen (oxaliplatin 100 mg/m(2) IV drip on days 1 and 15; leucovorin 400 mg/m(2) IV drip on days 1 and 15; 5‐FU 400 mg/m(2) IV bolus injection; 5‐FU 2.4/3.0 mg/m(2) continuous IV infusion for 48 hours on day 1, 2, 15, and 16; repeated every 4 weeks for at least 4 cycles)
Study: 20838324
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy (FAM and FOLFOX regimens combined)
Study: 10769552
Drug: 5 ppm
Normalized name: silver nitrate 55 PPM TOPICAL GEL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ppm inhaled nitric oxide
Study: 9237711
Drug: Pn‐CRM197 vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pn‐CRM197 vaccines (5 microg)
Study: 9237711
Drug: Pn‐CRM197 vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pn‐CRM197 vaccines (2 microg)
Study: 9237711
Drug: Pn‐CRM197 vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pn‐CRM197 vaccines (0.5 microg)
Study: 9237711
Drug: PS formulations
Normalized name: MENTHOL 10 mg in 100 mg / METHYL SALICYLATE 10 mg in 100 mg / EUCALYPTUS OIL 2 mg in 100 mg / CAMPHOR (NATURAL) 3 mg in 100 mg TOPICAL CREAM [Dr. Phillips Formulations Muscle Joint Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PS formulations
Study: 9237711
Drug: PS vaccines
Normalized name: Mumps vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: PS vaccines (5 microg)
Study: 9237711
Drug: Pn‐CRM197 vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pn‐CRM197 vaccines
Study: 9237711
Drug: HbOC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HbOC vaccine with Pn‐CRM197
Study: 8218691
Drug: Calcium mupirocin
Normalized name: Mupirocin Calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium mupirocin ointment (n = 170)
Study: 8218691
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment (n = 169)
Study: 24323641
Drug: safinamide 100
Normalized name: safinamide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: safinamide 100 mg/day
Study: 24323641
Drug: safinamide 50
Normalized name: safinamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: safinamide 50 mg/day
Study: 16677528
Drug: itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: itraconazole 200 mg Bid
Study: 16677528
Drug: itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: itraconazole 200 mg qd
Study: 12882842
Drug: Insulin 70/30
Normalized name: Insulin Human Isophane (NPH) 100 U/1 ML Subcutaneous Suspension [MIXTARD HUMAN INSULIN 70/30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin 70/30 mix plus metformin
Study: 12882842
Drug: Triple oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple oral therapy